The French pharmaceutical company Sanofi has upgraded its 2021 financial guidance for earnings per share (business EPS), it reports in a press release on Thursday morning.
Sanofi is now expecting growth of around 14 percent for its business EPS at current exchange rates (CER). The French firm also adjusted its business EPS guidance upward in connection with the second quarterly report of the year. Back then, it reported a new EPS guidance of 12 percent, compared to its previous full-year growth rate of a high single-digit figure.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
Quality System Manager 
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Communications Consultant 
SAP System Specialist (Product Supply) – Business Application Services 
Director Global Engineering 
Cell Culture Scientist/Senior Scientist 
Scientific Writer 
System Sales Development Consultant - Investment Projects, Merck Millipore 
Client Talent Acquisition Specialist 
(Senior) Drug Substance Specialist 
IRT Manager, Clinical Drug Supply 
Clinical Trial Manager 
Director for innovative pre-clinical testing unit